These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24801826)

  • 1. Effect of different "states" of sorbed water on amorphous celecoxib.
    Shete G; Kuncham S; Puri V; Gangwal RP; Sangamwar AT; Bansal AK
    J Pharm Sci; 2014 Jul; 103(7):2033-2041. PubMed ID: 24801826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular interactions in celecoxib-PVP-meglumine amorphous system.
    Gupta P; Bansal AK
    J Pharm Pharmacol; 2005 Mar; 57(3):303-10. PubMed ID: 15807985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
    Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
    Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of molecular interaction in stability of celecoxib-PVP amorphous systems.
    Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
    Mol Pharm; 2005; 2(5):384-91. PubMed ID: 16196491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
    Gupta P; Kakumanu VK; Bansal AK
    Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions.
    Andrews GP; Abu-Diak O; Kusmanto F; Hornsby P; Hui Z; Jones DS
    J Pharm Pharmacol; 2010 Nov; 62(11):1580-90. PubMed ID: 21072971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of surfactants on the crystal growth of amorphous celecoxib.
    Mosquera-Giraldo LI; Trasi NS; Taylor LS
    Int J Pharm; 2014 Jan; 461(1-2):251-7. PubMed ID: 24333451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and characterization of microcrystals for enhanced dissolution rate of celecoxib.
    Lakshmi K; Reddy MP; Kaza R
    Curr Drug Discov Technol; 2013 Dec; 10(4):305-14. PubMed ID: 24074306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.
    Gupta P; Bansal AK
    PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of celecoxib nanoparticles from volatile microemulsions.
    Margulis-Goshen K; Kesselman E; Danino D; Magdassi S
    Int J Pharm; 2010 Jun; 393(1-2):230-7. PubMed ID: 20403417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P; Chawla G; Bansal AK
    Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the crystal habit of celecoxib for improved processability.
    Banga S; Chawla G; Varandani D; Mehta BR; Bansal AK
    J Pharm Pharmacol; 2007 Jan; 59(1):29-39. PubMed ID: 17227618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Devitrification of amorphous celecoxib.
    Gupta P; Bansal AK
    AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility.
    Gupta P; Bansal AK
    Pharmazie; 2005 Nov; 60(11):830-6. PubMed ID: 16320944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
    Aucamp M; Milne M; Liebenberg W
    AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
    Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
    PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enthalpy relaxation studies of celecoxib amorphous mixtures.
    Kakumanu VK; Bansal AK
    Pharm Res; 2002 Dec; 19(12):1873-8. PubMed ID: 12523668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.